drugset
drugset / Trial / NCT02604212

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

NCT02604212 ↗

Phase 2 Terminated 32 enrolled Arrowhead Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.

Timeline

Start
2015-11
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ARC-520 Unknown 1 mg/kg Intravenous
Subject ARC-520 Unknown 2 mg/kg Intravenous
Background Cetirizine Other / unclassified 10 mg Oral
Background Chlorpheniramine Unknown 8 mg Oral
Background Diphenhydramine Unknown 50 mg Oral
Background Entecavir Small molecule 0.5 mg —
Background Entecavir Small molecule 1 mg —
Background Hydroxyzine Small molecule 50 mg Oral
Background Tenofovir Small molecule 300 mg —

Indications

hepatitis B virus infection